NM Coordinating Committee: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
Co-Chairs: P. David Mozley, MD; Anne Smith, PhD; John J.Sunderland, PhD | |||
<br />RSNA Staff Support: Julie Lisiecki | |||
[https://tinyurl.com/QIBA-NM-CC-Roster Roster] | [https://tinyurl.com/QIBA-NM-CC-Roster Roster] | ||
Revision as of 19:07, 26 January 2021
Co-Chairs: P. David Mozley, MD; Anne Smith, PhD; John J.Sunderland, PhD
RSNA Staff Support: Julie Lisiecki
Scope
The NM Coordinating Committee coordinates Biomarker Committees based on NM.
- Considering and proposing new candidate Biomarker Committees to the Steering Committee
- Preparing/Reviewing and Prioritizing groundwork funding proposals for submission to the Steering Committee
- Approving for publication Biomarker Profiles developed by the NM Biomarker Committees
- FDG-PET_Biomarker_Ctte
- PET_Amyloid_Biomarker_Ctte
- SPECT_Biomarker_Ctte
- TC99m Biomarker Committee [page coming soon]
- I-123 Biomarker Committee [page coming soon]
Meetings
- WebEx calls are held Quarterly. Please contact RSNA Staff for details.